Journal article

Clinical experience with the meningococcal B vaccine, Bexsero®: Prospects for reducing the burden of meningococcal serogroup B disease

Although rare, invasive meningococcal disease remains an important cause of mortality and morbidity in children and young adults. Vaccines have been successfully introduced to help protect against meningococcal disease caused by serogroups A, C, W and Y, but until recently, a vaccine for serogroup B (MenB) was not available. In many industrialised countries, MenB causes the majority of meningococcal disease. Moreover, MenB outbreaks occur unpredictably, particularly in high-risk populations, such as university students. In 2013, Bexsero® became the first broad-coverage vaccine to be licensed for active immunisation against MenB disease. Bexsero is now licensed in more than 35 countries worldwide for varying age groups, including the EU, Australia, Brazil, Canada, Chile, Uruguay and the USA.

Clinical recommendations for the use of Bexsero have been published in several countries. Recommendations include use in high-risk groups, outbreak control and routine infant immunisation. Since initial licensure, cons

Languages

  • English

Publication year

2016

Journal

Vaccine

Volume

7

Type

Journal article

Categories

  • Vaccines & delivery devices

Countries

  • Australia
  • Brazil
  • Canada
  • Chile
  • United States
  • Uruguay

Tags

  • Coverage monitoring
  • New vaccine introduction

WHO Regions

  • Region of the Americas
  • Western Pacific Region

Added by: Moderator

Added on: 2016-02-03 07:23:02

Hits: 1439